Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to individualize therapy.
Bruce D. Cheson, MD, of Georgetown University Hospital, and Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discuss whether lymphoma should be staged with a positron emission tomography (PET) scan and what follow-up scans are needed.
Wyndham H. Wilson, MD, PhD, of the National Cancer Institute, discusses the molecular underpinnings of diffuse large B-cell lymphoma and targeted treatments.
Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.
Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.
